Do Patients on Upadacitinib Need Labs? Dr. Janet Pope Save
Dr. Janet Pope discusses abstract OP00128, "Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Year of Exposure in Patients with Rheumatoid Arthritis Treated in the Select Phase 3 Program", presented at the virtual EULAR 2021 meeting.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.